Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women, ages \>18~* Fasting triglyceride ≥500 mg/dL and ≤2000 mg/dL~* Provide written informed consent and authorization for protected health information disclosure~Exclusion Criteria:~* Women who are pregnant or lactating, or planning to become pregnant~* Use of non-statin lipid-altering drugs which cannot be stopped including fibrates, niacin, fish oil and other products containing omega-3 fatty acids or other dietary supplements with potential lipid-altering effects~* History of pancreatitis~* History of bariatric surgery or currently on weight loss drugs~* Uncontrolled hypertension (BP \> 160/100)~* HIV infection or on treatment with HIV-protease inhibitors, cyclophosphamide,or isotretinoin~* Consumption of more than 2 alcoholic beverages per day~* History of cancers (except if been disease free for \>5 years OR history was basal or squamous cell skin cancer)~* Participation in another clinical trial involving an investigational agent in the last 30 days~* Other parameters will be assessed at the study center to ensure eligibility for this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- AMR101 (ethyl icosapentate) - 2 g/day (Type: EXPERIMENTAL): None
- AMR101 (ethyl icosapentate) - 4 g/day (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).